Memantine Ratiopharm

Memantine Hydrochloride, the active ingredient in Memantine Ratiopharm, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adult patients. The medication is manufactured under EU GMP standards and marketed throughout the European Union.

GNH USA supplies Memantine Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to strict regulatory requirements and provides reliable logistics for global distribution.

Memantine is an NMDA receptor antagonist used in the management of Alzheimer’s disease.

- Alzheimer’s disease (moderate to severe): helps maintain cognition and functional abilities. - Alzheimer’s disease (mild to moderate): may provide modest cognitive benefit. - Alzheimer’s disease (behavioral symptoms): can reduce agitation and aggression in some patients.

Memantine may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness: feeling of light‑headedness or unsteadiness. - Headache: mild to moderate head pain. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Seizures: occurrence of convulsive episodes. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hepatic injury: signs of liver dysfunction.

When prescribing Memantine, clinicians should consider several safety aspects.

- Renal impairment: dose may need adjustment in patients with reduced kidney function. - Hepatic impairment: monitor liver function and adjust dose if necessary. - History of seizures: use with caution and monitor for new seizure activity. - Concomitant NMDA antagonists: avoid combining with other drugs that block NMDA receptors. - Pregnancy: risk unknown; avoid use unless clearly needed. - Store at ambient temperature: keep in original container, protect from moisture and light.

Memantine can interact with other medicines, affecting its safety or effectiveness.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Other NMDA antagonists (e.g., ketamine): combined effect can cause severe CNS depression.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may reduce cognitive benefit of Memantine. - CNS depressants (benzodiazepines, opioids): may enhance sedation. - Diuretics: may alter plasma concentration of Memantine.